Frank McCormick, Ph.D., serves on the PellePharm board of directors.
Frank is a professor and director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center and co-founder of BridgeBio Pharma. Previously, Frank was co-founder and chief scientific officer of Onyx Pharmaceuticals, where he initiated and led drug discovery efforts leading to the approval of ONYX-015 in China for the treatment of nasophryngeal cancer. His group’s research also led to the identification of a CDK4 kinase inhibitor. Prior to Onyx, Frank worked with several Bay Area biotechnology companies, including Cetus Corporation, where he served as director of molecular biology and vice president of research, and Chiron Corporation, where he served as vice president of research.
Frank is the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF, and has served as president for the American Association for Cancer Research (AACR). Currently, he oversees an NCI-supported national effort to develop therapies against Ras-driven cancers at the Frederick National Lab for Cancer Research.
Frank earned his Ph.D. in biochemistry from the University of Cambridge and his bachelor’s degree in biochemistry from the University of Birmingham in England. He is a Fellow of the Royal Society. He is the author of over 285 scientific publications and holds 20 issued patents.